Results 171 to 180 of about 117,113 (304)

Delivery of nano‐formulated drugs to solid tumours is selectively increased by co‐application of the vascular disrupting agent CA4P

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and purpose Nano‐formulated chemotherapeutics prolong systemic availability of drugs and can reduce systemic toxicity, but their accumulation in solid tumours is often limited and unpredictable. Broadly applicable strategies to selectively enhance tumour delivery are lacking.
Annabel Kitowski   +13 more
wiley   +1 more source

Hypogonadotropic Hypogonadism Before and After Transsphenoidal Surgery for Non‐Functioning Pituitary Adenoma

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective The effect of transsphenoidal surgery (TSS) on the hypothalamic‐pituitary‐gonadal (HPG) axis in patients with non‐functioning pituitary adenomas (NFPA) is underexplored, especially in women. Our aim was to investigate the HPG axis function before and after TSS, its association with quality of life (QoL), and to identify factors that ...
Victor Hantelius   +6 more
wiley   +1 more source

Clinical Outcomes of Adrenalectomy for Metastatic Adrenal Tumor: A 30-case Single-center Study. [PDF]

open access: yesCancer Diagn Progn
Nishida M   +9 more
europepmc   +1 more source

Obesity in Classic Congenital Adrenal Hyperplasia: Mechanisms, Complications and Management

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Classic congenital adrenal hyperplasia (CCAH) is an autosomal recessive genetic disorder primarily caused by 21‐hydroxylase deficiency. Although the survival rate of patients has significantly improved with glucocorticoid replacement therapy, long‐term use of supraphysiological doses and multiple factors inherent to the disease itself have led
Jialin Mu   +5 more
wiley   +1 more source

Rare Primary Adrenal Tumor: A Case Report of Teratomas and Literatures Review. [PDF]

open access: yesFront Oncol, 2022
Wang X   +8 more
europepmc   +1 more source

Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease. Design LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol ...
John Newell‐Price   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy